Ethambutol
- Generic Name
- Ethambutol
- Brand Names
- Etibi, Myambutol
- Drug Type
- Small Molecule
- Chemical Formula
- C10H24N2O2
- CAS Number
- 74-55-5
- Unique Ingredient Identifier
- 8G167061QZ
- Background
Ethambutol is a bacteriostatic agent indicated alongside medications such as isoniazid, rifampin, and pyrazinamide in the treatment of pulmonary tuberculosis. Ethambutol was first described in the literature in 1961. It was developed out of a need for therapies active against isoniazid resistant strains of Mycobacterium tuberculosis.
...
- Indication
Ethambutol is indicated in combination with other anti-tuberculosis drugs in the treatment of pulmonary tuberculosis. Ethambutol is commonly used in combination with isoniazid, rifampin, and pyrazinamide.
- Associated Conditions
- Mycobacterium Avium Intracellulare Complex (MAC), Mycobacterium Infections, Pulmonary Tuberculosis (TB)
- Associated Therapies
- -
Linezolid Instead of Ethambutol in Treatment of Drug-susceptible Tuberculosis
- Conditions
- Interventions
- First Posted Date
- 2013-11-25
- Last Posted Date
- 2014-12-30
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 429
- Registration Number
- NCT01994460
- Locations
- 🇰🇷
Seoul National University Bundang Hospital, Seongnam, Kyunggi, Korea, Republic of
🇰🇷National Medical Center, Seoul, Korea, Republic of
🇰🇷SMG-SNU Boramae Medical Center, Seoul, Korea, Republic of
Evaluation of SQ109, High-dose Rifampicin, and Moxifloxacin in Adults With Smear-positive Pulmonary TB in a MAMS Design
- Conditions
- Interventions
- First Posted Date
- 2013-02-07
- Last Posted Date
- 2017-09-20
- Lead Sponsor
- Michael Hoelscher
- Target Recruit Count
- 365
- Registration Number
- NCT01785186
- Locations
- 🇿🇦
The Aurum Institute for Health Research, Johannesburg, South Africa
🇿🇦University of Cape Town, Centre for Tuberculosis Research Innovation, Cape Town, South Africa
🇹🇿NIMR - Mbeya Medical Research Programme, Mbeya, Tanzania
Rifampin-Based Tuberculosis Treatment Versus Rifabutin-Based Tuberculosis Treatment in Persons With HIV
- First Posted Date
- 2012-05-18
- Last Posted Date
- 2018-02-13
- Target Recruit Count
- 71
- Registration Number
- NCT01601626
- Locations
- 🇵🇪
Asociacion Civil Impacta Salud y Educacion - Miraf CRS (11301), Lima, Peru
🇧🇷Instituto de Pesquisa Clinica Evandro Chagas (12101), Rio de Janeiro, Brazil
🇭🇹Les Centres GHESKIO CRS (30022), Port-au-Prince, Haiti
Essentiality of INH in TB Therapy
- Conditions
- Interventions
- First Posted Date
- 2012-05-02
- Last Posted Date
- 2018-04-06
- Target Recruit Count
- 69
- Registration Number
- NCT01589497
- Locations
- 🇿🇦
TASK Applied Science CRS (31718), Bellville, South Africa
🇿🇦University of Cape Town Lung Institute (UCTLI) CRS (31792), Cape Town, Western Cape, South Africa
Effect of Weight and/or Obesity on Ethambutol Drug Concentrations
- First Posted Date
- 2010-01-14
- Last Posted Date
- 2013-01-24
- Lead Sponsor
- Texas Tech University Health Sciences Center
- Target Recruit Count
- 18
- Registration Number
- NCT01048697
- Locations
- 🇺🇸
University of Texas Southwestern Medical Center, Dallas, Texas, United States
Tuberculosis Treatment Shortening Trial
- Conditions
- Interventions
- First Posted Date
- 2005-08-15
- Last Posted Date
- 2018-11-08
- Target Recruit Count
- 394
- Registration Number
- NCT00130247
- Locations
- 🇧🇷
Universidade Federal do Espirito Santo - Duke Hubert-Yeargan Center, Vitória, Espírito Santo, Brazil
🇺🇬Mulago Hospital Complex, Kampala, Uganda
🇵🇭Makati Medical Center, Makati, National Capital Region, Philippines
Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
- Conditions
- Interventions
- Drug: darunavir/ritonavir dosage #1Drug: TAF w/cobicistatDrug: TAF w/cobicistat or ritonavirDrug: tenofovir alafenamide fumarate (TAF)Drug: elvitegravir/cobicistatDrug: darunavir/cobicistatDrug: atazanavir/cobicistatDrug: lopinavir/ritonavir dosage #1Drug: atazanavir/ritonavir/tenofovir dosage #1Drug: lopinavir/ritonavir dosage #2Drug: indinavir/ritonavir dosage #1Drug: fosamprenavir/ritonavirDrug: atazanavir/ritonavir dosage #1Drug: didanosine delayed release (Videx® EC)Drug: emtricitabineDrug: nelfinavir dosage #1Drug: tipranavir/ritonavirDrug: etravirineDrug: darunavir/ritonavir dosage #4Drug: indinavir/ritonavir dosage #2Drug: rilpivirineDrug: ethambutolDrug: efavirenzDrug: raltegravirDrug: dolutegravirDrug: kanamycinDrug: nevirapineDrug: amprenavirDrug: abacavirDrug: tenofovirDrug: maravirocDrug: darunavir/ritonavir dosage #2Drug: lopinavir/ritonavir dosage #3Drug: lopinavir/ritonavir dosage #4Drug: tenofovir/atazanavir/ritonavir dosage #2Drug: atazanavir/ritonavir dosage #2Drug: nelfinavir dosage #2Drug: rifampicinDrug: amikacinDrug: darunavir/ritonavir dosage #3Drug: etonogestrel implantDrug: capreomycinDrug: ethinyl estradiolDrug: isoniazidDrug: moxifloxacinDrug: levoflaxacinDrug: pyrazinamideDrug: ofloxacinDrug: ethionamide/prothionamideDrug: terizidone/cycloserineDrug: para-aminosalicylic acid (PAS)Drug: high dose INHDrug: bedaquilineDrug: clofazamineDrug: delamanidDrug: linezolidDrug: pretomanid
- First Posted Date
- 2002-08-01
- Last Posted Date
- 2022-07-22
- Target Recruit Count
- 1578
- Registration Number
- NCT00042289
- Locations
- 🇺🇸
Usc La Nichd Crs, Los Angeles, California, United States
🇿🇦Wits RHI Shandukani Research Centre CRS, Johannesburg, Gauteng, South Africa
🇺🇸Boston Medical Center Ped. HIV Program NICHD CRS, Boston, Massachusetts, United States
TBTC Study 24: Intermittent Treatment of TB With Isoniazid Resistance or Intolerance
- Conditions
- Interventions
- First Posted Date
- 2001-09-10
- Last Posted Date
- 2011-08-03
- Lead Sponsor
- Centers for Disease Control and Prevention
- Target Recruit Count
- 98
- Registration Number
- NCT00023374
- Locations
- 🇺🇸
New York University School of Medicine, New York, New York, United States
🇨🇦University of British Columbia, Vancouver, British Columbia, Canada
🇺🇸Washington, D.C. VAMC, Washington, District of Columbia, United States
Phase II Study of Amithiozone (Thiacetazone) for Patients With Mycobacterium Avium Complex Pulmonary Disease
- Conditions
- First Posted Date
- 2000-02-25
- Last Posted Date
- 2015-03-25
- Lead Sponsor
- National Jewish Health
- Target Recruit Count
- 50
- Registration Number
- NCT00004689
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.